We're #hiring a new Contract Clinical Research Associate in Boston, Massachusetts. Apply today or share this post with your network.
Autobahn Therapeutics, Inc.
Biotechnology Research
San Diego, CA 8,013 followers
Restoring hope for people affected by CNS disorders
About us
Autobahn Therapeutics is focused on improving life health for people affected by CNS disorders by driving the regenerative power of the human body. Altering the progressive and debilitating course of these conditions by returning the brain to a healthier state will transcend the benefits offered by existing therapies and allow people to live the futures they deserve. CNS drug development has long suffered from limited innovation and high failure rates, especially for drugs that strive to modify the underlying cause of disease. Developing successful therapies requires several factors, including a deep knowledge of underlying disease mechanisms, exceptional chemistry, insights into viable translational models and strategies to match the right patients to the most effective drugs. We have brought these elements together at Autobahn to make a real difference in the lives of people. We are leveraging a deep understanding of validated human biology coupled with a brain-targeting chemistry platform to develop novel, small molecule therapies that harness the regenerative power of the human body, with an initial focus on high unmet need areas neuropsychiatry, neurodegeneration, and neuroinflammation. Our pipeline is led by ABX-002, a centrally-penetrant thyroid hormone receptor beta (TRβ) agonist being developed as a potential adjunctive treatment for people with major depressive disorder and bipolar disorder depression. Want to join our team? Please see our open positions on the Careers page of the Autobahn website: https://autobahntx.com/careers/
- Website
-
http://autobahntx.com
External link for Autobahn Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- San Diego, CA
- Type
- Privately Held
- Founded
- 2017
Locations
-
Primary
Get directions
9880 Campus Point Drive
Suite 440
San Diego, CA 92121, US
Employees at Autobahn Therapeutics, Inc.
Updates
-
Autobahn will participate in the 2025 Jefferies London Healthcare Conference, where we look forward to connecting with the investment community to share updates on our two Phase II trials of elunetirom in #majordepressivedisorder and #bipolardepression. For more details: https://lnkd.in/g9Hyk6HB
-
We're #hiring a new Associate Director Project Management in San Diego Metropolitan Area. Apply today or share this post with your network.
-
As we near the end of October, our vision for the future of mental health treatment continues to drive our innovation at Autobahn Therapeutics. We envision a world where people affected by CNS disorders have access to treatments that provide meaningful benefits and drive improvements to overall quality of life. Our work continues well beyond awareness months. Every day, we’re advancing toward our goal of creating transformative medicines for conditions like major depressive disorder, bipolar depression, and other CNS disorders. Join us on this journey: autobahntx.com #FutureOfMentalHealth #CNSInnovation #MDD #BipolarDepression #MentalHealthAwareness
-
We're #hiring a new Contract Clinical Research Associate in San Diego Metropolitan Area. Apply today or share this post with your network.
-
Today marks both World Mental Health Day and National Depression Screening Day, two important reminders of the global need for mental health prioritization and early intervention. World Mental Health Day highlights the critical importance of addressing mental health challenges that affect millions worldwide. At Autobahn Therapeutics, we’re not just advocating for mental health awareness, we’re actively developing innovative treatments for conditions like major depressive disorder and bipolar depression. The path to better mental health requires both awareness and action. We’re committed to both. Learn more about our ongoing clinical trials: https://lnkd.in/gijEBXce #WorldMentalHealthDay #DepressionScreeningDay #CNSInnovation #MDD #BipolarDepression #MentalHealthMatters #MentalHealthAwareness
-
Autobahn is seeking a Director, Clinical Science to join our team dedicated to restoring hope for individuals impacted by CNS disorders. If you are passionate about making a difference, consider applying or sharing this opportunity with your network! https://lnkd.in/gRVkhdFe
-
Mental Illness Awareness Week begins today, marking over three decades of NAMI's dedication to reducing stigma and promoting understanding of mental health conditions. At Autobahn Therapeutics, we recognize that addressing mental illness requires both community support and scientific innovation. While organizations like NAMI provide crucial education and advocacy, we’re working to develop treatments that target the underlying biology of CNS disorders. Discover our programs: https://lnkd.in/g-pnDHg7 #MentalIllnessAwarenessWeek #NAMI #CNSInnovation #MentalHealthSupport #MentalHealthAwareness
Mental Illness Awareness Week is here! 💚 This year’s theme is Building Community: Supporting Mental Well-Being Together. Mental health affects everyone — and no one should have to face challenges alone. Join NAMI and communities across the country in raising awareness, fighting stigma, and building support. ➡️ nami.org/MIAW #MIAW #MentalHealthAwareness #MentalHealthMatters #EndTheStigma #ThisIsMyCommunity
-
-
October is National Depression and Mental Health Screening Month, a time dedicated to raising awareness about depression and the importance of accessible mental health screenings. At Autobahn Therapeutics, our commitment to developing transformative treatments for CNS disorders extends beyond awareness. It’s about creating real solutions for the millions affected by conditions like major depressive disorder (MDD) and bipolar depression. This month and every month, we remain focused on harnessing the regenerative power of the human body to restore the brain to a healthier state. Learn more about our approach: autobahntx.com #MentalHealthAwareness #MDD #BipolarDepression #CNSInnovation #MentalHealthMatters
-
We are incredibly proud to congratulate our Founder, Tom Scanlan, on receiving the prestigious Sidney H. Ingbar Distinguished Lectureship Award from the American Thyroid Association, Inc. (ATA). This lifetime achievement honor recognizes Dr. Scanlan’s outstanding academic achievements and major contributions to thyroid-related research. Tom’s groundbreaking work in centrally penetrant thyromimetic prodrugs laid the scientific foundation for Autobahn’s innovative approach to developing CNS therapeutics. By building on decades of his foundational research, we’re working to transform the lives of people affected by CNS disorders. #atathyroid2025 #ThyroidResearch #CNSInnovation #ScientificExcellence